Insider Selling: Phreesia (NYSE:PHR) Director Sells $24,263.38 in Stock

Phreesia, Inc. (NYSE:PHR) Director Lisa Egbuonu-Davis sold 2,546 shares of the business’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $9.53, for a total transaction of $24,263.38. Following the transaction, the director directly owned 38,316 shares in the company, valued at approximately $365,151.48. The trade was a 6.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Phreesia Stock Performance

Phreesia stock opened at $9.96 on Monday. Phreesia, Inc. has a 12-month low of $7.77 and a 12-month high of $32.76. The company has a market capitalization of $615.94 million, a price-to-earnings ratio of 66.43 and a beta of 0.91. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.76 and a quick ratio of 1.76. The firm’s fifty day moving average price is $9.35 and its 200 day moving average price is $11.93.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, May 27th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $130.94 million during the quarter, compared to the consensus estimate of $130.08 million. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.Phreesia’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.07) earnings per share. On average, research analysts forecast that Phreesia, Inc. will post 0.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on PHR shares. Truist Financial upped their target price on Phreesia from $11.00 to $12.00 and gave the company a “hold” rating in a report on Thursday, May 28th. Citigroup reissued a “market perform” rating on shares of Phreesia in a report on Friday, May 29th. Mizuho reduced their price objective on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. BMO Capital Markets lowered their price objective on Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. Finally, Piper Sandler lowered Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a research report on Thursday, May 28th. Nine equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $16.65.

Key Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analysts are still viewing Phreesia as a “Hold,” suggesting the stock’s long-term outlook is not being broadly written off by Wall Street. Phreesia, Inc. (NYSE:PHR) Given Consensus Rating of “Hold” by Brokerages
• Neutral Sentiment: A director, Lisa Egbuonu-Davis, sold 2,546 shares in a pre-arranged Rule 10b5-1 transaction. While insider sales can attract attention, the filing indicates it was scheduled in advance rather than a discretionary move. Director stock sale disclosure
• Negative Sentiment: Phreesia is facing repeated investor alerts from law firms about a securities fraud class action, which may keep pressure on the stock until the deadline passes and more clarity emerges. Phreesia investigation alert
• Negative Sentiment: Several firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter, The Gross Law Firm, the Schall Law Firm, and DJS Law Group, are urging investors to participate in the class action before the July 13 deadline, reinforcing the legal risk narrative. Phreesia sued for securities law violations

Institutional Investors Weigh In On Phreesia

Hedge funds have recently modified their holdings of the stock. NewEdge Advisors LLC increased its stake in Phreesia by 2,395,000.0% in the 1st quarter. NewEdge Advisors LLC now owns 23,951 shares of the company’s stock worth $201,000 after purchasing an additional 23,950 shares in the last quarter. Essential Partners LLC lifted its stake in Phreesia by 2,016.6% during the first quarter. Essential Partners LLC now owns 9,313 shares of the company’s stock valued at $78,000 after buying an additional 8,873 shares in the last quarter. Bank of America Corp DE lifted its stake in Phreesia by 142.6% during the first quarter. Bank of America Corp DE now owns 1,001,057 shares of the company’s stock valued at $8,389,000 after buying an additional 588,444 shares in the last quarter. Amundi acquired a new position in shares of Phreesia in the first quarter worth about $401,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Phreesia by 1,119.8% in the first quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock worth $27,000 after buying an additional 3,001 shares during the period. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.